Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sarizotan (EMD 128130) is an orally active compound that acts as an agonist for serotonin 5-HT 1A receptors and dopamine receptors. It has shown potent activity with IC 50 values of 6.5 nM for rat 5-HT 1A , 0.1 nM for human 5-HT 1A , 15.1 nM for rat D 2 , 17 nM for human D 2 , 6.8 nM for human D 3 , and 2.4 nM for human D 4.2 .
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,220 | 5日内发货 | ||
5 mg | ¥ 2,270 | 5日内发货 | ||
25 mg | ¥ 7,690 | 6-8周 | ||
50 mg | ¥ 9,990 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,280 | 5日内发货 |
Sarizotan 的其他形式现货产品:
产品描述 | Sarizotan (EMD 128130) is an orally active compound that acts as an agonist for serotonin 5-HT 1A receptors and dopamine receptors. It has shown potent activity with IC 50 values of 6.5 nM for rat 5-HT 1A , 0.1 nM for human 5-HT 1A , 15.1 nM for rat D 2 , 17 nM for human D 2 , 6.8 nM for human D 3 , and 2.4 nM for human D 4.2 . |
靶点活性 | 5-HT2A receptor:587 nM (IC50, human, antagonist site), 5-HT2A receptor:960 nM (IC50, rat, agonist site), 5-HT2C receptor:800 nM (IC50, pig), 5-HT6 receptor:3300 nM (IC50, human), 5-HT7 receptor:10 nM (IC50, human), 5-HT3 receptor:3500 nM (IC50, NG 108 cells), D3 receptor:6.8 nM (IC50, human), 5-HT2B receptor:108 nM (IC50, human), 5-HT1A receptor:0.1 nM (IC50, human), 5-HT1A receptor:6.5 nM (IC50, rat), 5-HT1B receptor:600 nM (IC50, rat), 5-HT5A receptor:313 nM (IC50, human), D 4.2:2.4 nM (IC50, human), D2 receptor:15.1 nM (IC50, rat), D2 receptor:17 nM (IC50, human), 5-HT1D receptor:500 nM (IC50, calf) |
体外活性 | Sarizotan concentration-dependently inhibits the electrically-induced contractions with an IC 50 value of 150 nM (E max 40% at 1 mM)[1]. |
体内活性 | Sarizotan (3, 10 mg/kg, po) at the higher dose slightly decreases 5-HT in the striatum and its metabolite 5-HIAA in frontal cortex and hippocampus. Sarizotan (10 mg/kg, po) substantially increases the DA metabolites DOPAC and HVA in the striatum and frontal cortex[1]. Sarizotan represents a new approach for the treatment of extrapyramidal motor complications such as l-DOPA-induced dyskinesia in Parkinson’s disease[1]. Sarizotan (10 ng and 1 μg, local administration) attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats[2]. Animal Model: Male Sprague-Dawley rats weighing 220-240 g (exhibiting a vigorous rotational response)[2]. Dosage: 1 ng, 10 ng and 1 μg in 0.3 μL solution. Administration: Administered via an injection cannula inserted to the guide cannula through the STN (V -8.4 mm from skull) with the injection cannula connected to a 10-μL syringe and mounted on a microinfusion pump for 22 consecutive days. Result: On day 23, the subthalamic administration of Sarizotan at the higher doses tested (10 ng and 1 μg) significantly decreased the total dyskinesia score in levodopa-treated rats in comparison with the rats treated only with levodopa (p<0.05, p<0.01, respectively). |
别名 | EMD 128130 |
分子量 | 348.421 |
分子式 | C22H21FN2O |
CAS No. | 351862-32-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sarizotan 351862-32-3 EMD128130 EMD 128130 EMD-128130 Inhibitor inhibitor inhibit